source
- Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCLRituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.
- Nivolumab added to standard radiation and hormone therapy yields 90% two-year disease control in high-risk prostate cancerA Phase 2 trial evaluated the combination of nivolumab with standard radiation and hormone therapy in patients with high‑volume grade group 5 prostate cancer. The study reported a 2‑year freedom f…